Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and ... other therapeutic areas.

As of June 30, 2025, the company's diverse portfolio includes 71 brands across therapeutic areas like women’s healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals (including vitamins/minerals/nutrition, gastrointestinal, and respiratory).

The company has a pan-India marketing and distribution network with 2,671 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.

The company has two manufacturing facilities, located in the state of Gujarat , with an aggregate installed capacity for formulations of 1,285.44 million units per annum.

Strengths

• Second fastest growing company within the top 30 pharmaceutical companies in the Indian pharmaceutical market by domestic sales between MAT June 2022 and MAT June 2025.
• Demonstrated capabilities of building a diversified portfolio, including "engine" brands, in our targeted therapy areas.
• Pan-India sales network and marketing strategy focused on the "middle of the pyramid" target market.
• Quality and current Good Manufacturing Practices-focused manufacturing facilities, with strong research and development capabilities, are driving a portfolio of differentiated pharmaceutical products.
• Qualified, experienced, and entrepreneurial management team supported by marquee investors.

Risks
 

• The therapeutic areas of women`s healthcare, cardio-diabeto, and pain management contributed to an aggregate of Rs.2,257.26 million (or 65.14%) and Rs.7,465.54 million (or 62.40%) of our revenue from operations for the three months ended June 30, 2025 and the Financial Year 2025, respectively. If our products in these or other therapeutic areas which contribute significantly to our revenue from operations do not perform as expected or if competing products become available and gain wider market acceptance, our business, results of operations, financial condition and cash flows may be adversely affected.
• Our 27 "engine" brands (and in particular, our B-29 and Myoril brands) accounted for 72.34% of our domestic sales during the MAT June 2025 period, and any adverse developments affecting the sales of our "engine" brands could have an adverse effect on our business, results of operations, financial condition and cash flows.
• We derive a significant majority of our revenue from our operations within India (constituting 96.34% and 96.33% of our revenue from operations during the three months ended June 30, 2025 and the Financial Year 2025, respectively). In the event of a fall in demand for our products in India, or if we fail to successfully expand into international markets, our business, results of operations, financial conditions and cash flows may be adversely affected.
• A significant portion of our domestic sales are concentrated in the states of Gujarat, Maharashtra, Chhattisgarh, Goa and Madhya Pradesh (accounting for 47.30% of our domestic sales for MAT June 2025). Any adverse developments affecting our sales in these regions could have an adverse effect on our business, results of operations, financial condition and cash flows.
• 70.10% of our domestic sales for MAT June 2025 were derived from chronic and sub-chronic therapeutic segments, which are subject to risks and uncertainties that could adversely affect our business, results of operations, financial condition and cash flows.